Patents by Inventor Manuel Angel Gonzalez de la Peña

Manuel Angel Gonzalez de la Peña has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 11672831
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: June 13, 2023
    Assignees: Takeda Pharmaceutical Company Limited, Universidad Autónoma de Madrid
    Inventors: María Gema Fernández Miguel, Manuel Ángel González De La Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 11660318
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 30, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: María Gema Fernández Miguel, Manuel Ángel González De La Pena, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
    Publication number: 20220313742
    Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 6, 2022
    Inventors: Dirk BÜSCHER, Manuel Angel GONZÁLEZ DE LA PENA, Mario Delgado Mora
  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 10780132
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: September 22, 2020
    Assignees: TiGenix, S.A.U., Universidad Autónoma de Madrid
    Inventors: María Gema Fernández Miguel, Manuel Ángel González De La Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 10758575
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: September 1, 2020
    Assignees: TiGenix, S.A.U., UNIVERSIDAD AUTÓNOMA DE MADRID
    Inventors: María Gema Fernández Miguel, Manuel Ángel González De La Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue
    Patent number: 10729726
    Abstract: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising the cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: August 4, 2020
    Assignees: TIGENIX, S.A.U., UNIVERSIDAD AUTÓNOMA DE MADRID
    Inventors: Rosa Ana García Castro, María Gema Fernández Miguel, Mariano García Arranz, Manuel Angel González De La Peña, Damián García Olmo
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20200206274
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 2, 2020
    Applicants: TiGenix, S.A.U., Universidad Autonoma de Madrid
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Angel GONZALEZ DE LA PENA, Rosa Ana GARCIA CASTRO, Mariano GARCIA ARRANZ, Damian GARCIA-OLMO
  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 10548924
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: February 4, 2020
    Assignees: TIGENIX, S.A.U., UNIVERSIDAD AUTONOMA DE MADRID
    Inventors: Maria Gema Fernandez Miguel, Manuel Angel Gonzalez De La Pena, Rosa Ana Garcia Castro, Mariano Garcia Arranz, Damian Garcia-Olmo
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20190269737
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: February 1, 2019
    Publication date: September 5, 2019
    Applicants: TiGenix, S.A.U., Universidad Autónoma de Madrid
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
  • Cell populations having immunoregulatory activity, method for isolation and uses
    Patent number: 9943550
    Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: April 17, 2018
    Assignees: TIGENIX, S.A.U., CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Dirk Büscher, Manuel Angel González De La Peña, Mario Delgado Mora
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
    Publication number: 20170296592
    Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 19, 2017
    Inventors: Dirk BÜSCHER, Manuel Angel GONZÁLEZ DE LA PEÑA, Mario Delgado MORA
  • IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
    Publication number: 20170296585
    Abstract: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.
    Type: Application
    Filed: August 24, 2015
    Publication date: October 19, 2017
    Inventors: Rosa Ana GARCÍA CASTRO, María Gema FERNÁNDEZ MIGUEL, Mariano GARCÍA ARRANZ, Manuel Angel GONZÁLEZ DE LA PEÑA, Damián GARCÍA OLMO
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
    Publication number: 20170296593
    Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 19, 2017
    Inventors: Dirk BÜSCHER, Manuel Angel GONZÁLEZ DE LA PEÑA, Mario Delgado MORA
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20170209496
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 27, 2017
    Applicants: TiGenix, S.A.U., Universidad Autónoma de Madrid
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20170189452
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Applicants: TiGenix, S.A.U., Universidad Autónoma de Madrid
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20170189451
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stern cells for treating fistulae.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Applicants: TiGenix, S.A.U., Universidad Autónoma de Madrid
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
  • Use of adipose tissue-derived stromal stem cells in treating fistula
    Patent number: 8999709
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: April 7, 2015
    Assignees: Tigenix, S.A.U., Universidad Autonoma de Madrid
    Inventors: María Gema Fernández Miguel, Manuel Angel González de la Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20150065948
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Inventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
  • USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA
    Publication number: 20140072539
    Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 13, 2014
    Applicants: TIGENIX, S.A.U., Universidad Autonoma de Madrid Ciudad Universitario de Cantoblanco
    Inventors: Maria Gema Fernandez Miguel, Manuel Angel Gonzalez De La Pena, Rosa Ana Garcia Castro, Mariano Garcia Arranz, Damian Garcia-Olmo
  • BIOACTIVE SURFACE CAPABLE OF GENETICALLY MODIFYING BIOLOGICAL CELLS OR TISSUES AND USE THEREOF
    Publication number: 20140023711
    Abstract: The invention relates to a bioactive surface comprising a polymer matrix, a connecting complex comprising at least one compound covalently bound to the surface of the polymer matrix, and a gene transfer vector bound to the connecting complex, wherein the compound of the complex is covalently bound to the transfer vector using a group selected from among carboxyl, amino, isocyanate and hydroxyl. The invention also relates to the use of the bioactive surface for transferring a nucleic acid to a cell. The invention further relates to: an implantable device characterized in that at least part of the surface thereof is coated with said bioactive surface, and to the use of the implantable device for transferring a nucleic acid to a cell. In addition, the invention relates to a method for transferring a nucleic acid to a cell and to a kit for performing said method.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 23, 2014
    Inventors: Manuel Angel Gonzalez De La Pena, Juan Carlos Ramirez Martinez, Anna Cifuentes, Antonio Bernad Miana, Salvador Borros Gomez, David Horna Tomas